After Ozempic: the next-gen weight-loss drugs coming next

Why there's an "after Ozempic" at all

Semaglutide, sold as Ozempic and Wegovy, is a single GLP-1 agonist. It was the first drug to make double-digit weight loss look routine, and it opened the whole category. Almost everything behind it in the pipeline does one of three things it doesn't: adds a second hormone signal (GIP, glucagon, or amylin), stacks a third, or moves the drug out of a weekly shot and into a daily pill.

That's the real story of "next-gen." Not a better version of the same thing. A different receptor combination, or a different delivery, aimed at more loss or fewer needles.

Here is the pipeline people actually mean when they search this, with the furthest clinical stage each compound has reached as of mid-2026 and the strongest weight-loss result it has reported. Read the caution under the table before you rank anything by the biggest number.

The catch: these numbers are not head-to-head

The single most misleading thing you can do with the table above is line the percentages up and crown a winner. They come from different trials, different lengths, different doses, and different phases. A Phase 2 number at 13 weeks and a Phase 3 number at 80 weeks are not the same measurement.

Two rules keep you honest:

• Longer trials show bigger loss. Weight keeps coming off for a year or more. A 13-week result and an 80-week result can't be compared directly, and the shorter one is understating where that drug would land.
• Early-phase numbers are provisional. Phase 2 figures come from smaller, shorter, more controlled trials. The average can move up or down once a drug reaches a large, long Phase 3, so treat any pre-Phase-3 number as a first read, not the final one.
• The same trial reports more than one number. A drug's loss depends on which analysis you cite (everyone assigned to it versus only those who stuck with it) and which dose. That's why a single compound shows up as a range.

So the table tells you what stage each compound has reached and roughly what it can do. It does not tell you which is strongest. Only a head-to-head trial does that, and most of these have never been tested against each other.

The triple agonist: Retatrutide

Retatrutide is the one drawing the most attention, because it hits three receptors at once (GLP-1, GIP, and glucagon) and its Phase 3 loss held up. In the TRIUMPH-1 trial it reached roughly 25 to 28 percent at 80 weeks depending on how the data is analyzed, and a subgroup that completed treatment reached close to 30 percent, which is territory usually associated with surgery. Company guidance points to a US filing around late 2026, which would make it the closest next-gen compound to actually reaching the market. Full profile: Retatrutide.

The amylin route: CagriSema and Amycretin

These two attack appetite through a different pathway, amylin, on top of GLP-1.

CagriSema is the combination approach: semaglutide and cagrilintide dosed together in one weekly shot. Its pivotal Phase 3 trials are done and it is under FDA review, so it could be one of the first amylin-based options to actually land.

Amycretin is the same idea built into a single molecule instead of a combination, and it comes in both an injectable and an oral form. It moved into Phase 3 in early 2026, which puts any approval years out, but it is the one to watch if the single-molecule bet pays off.

The dual agonists still in trials: VK2735 and Survodutide

VK2735 is a GLP-1 and GIP dual agonist, the same broad mechanism as tirzepatide, with both a weekly injectable and a once-daily oral tablet in development. The injectable is in Phase 3; the oral form is heading there. It is the compound the "needle-free" crowd tracks most closely.

Survodutide pairs GLP-1 with glucagon, which adds a metabolic-rate signal on top of appetite suppression. Its Phase 3 SYNCHRONIZE-1 trial reported about 16.6% loss at 76 weeks, and it carries a breakthrough-therapy designation for MASH (fatty liver disease), so its story is as much about the liver as the scale.

Already approved, just not here: Mazdutide

Mazdutide is a GLP-1 and glucagon dual agonist that is already approved in China for weight management, based on Phase 3 data. It is not FDA-approved and is not sold in the US. It matters because it shows the dual GLP-1/glucagon mechanism clearing a real regulator, not just a trial.

The other shift: pills, not just shots

Most of the drugs above are weekly shots. The change a lot of needle-averse people care about is oral delivery, and that door is already open. Oral semaglutide has been around for years (a diabetes pill since 2019, then approved for weight management in late 2025), and in early 2026 the first small-molecule GLP-1 pill was approved. Unlike the peptide pills, that one can be taken any time of day, with or without food.

Oral VK2735 and oral amycretin are still in trials behind them. How an oral version stacks up against its injectable sibling varies by compound: oral VK2735 showed a bit less loss than the injectable at the same 13-week mark, while oral semaglutide landed close to its shot. So "pill" does not automatically mean "weaker." It depends on the specific drug and how it is dosed.

Bottom line

The pattern behind "after Ozempic" is simple: more receptors, or a pill instead of a needle. Retatrutide and CagriSema are the closest to the US market. Amycretin, VK2735, and survodutide are further out but each carries a distinct angle (single-molecule amylin, oral dual-agonist, liver disease). Mazdutide is approved, but in China.

None of this is a buy signal. Most of these are trial-only or unapproved, which means anything sold outside a clinical trial is unverified by definition, and source quality matters more the earlier a compound is. Educational only, not medical advice.

Go deeper:

• Compare any two of these head to head, the real per-pair verdicts
• The full peptide index, stage, evidence tier, and status for every compound
• The Honest Peptide Report Card, hype versus evidence across the most-searched peptides